Skip to content

Pre-menstruation symptoms management.

A STUDY TO ASSESS THE EFFICACY OF ASHWAGANDHA CHURNA IN PRE MENSTRUAL SYNDROME. - PMS

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/102613
Enrollment
80
Registered
2026-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N943- Premenstrual tension syndrome

Interventions

None listed

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Females having regular menstrual cycle Females presenting mild to moderate symptoms of PMS Symptoms should appear only in luteal phase of menstrual cycle Females willing for treatment

Exclusion criteria

Exclusion criteria: Females having irregular menstrual cycle Females with symptoms in first 13 days of cycle Females presenting severe symptoms of PMS Perimenopausal females Females on hormonal therapy or OC pills Patients having any uterine pathology Females diagnosed with affective disorder Chronic medical conditions like DM HT Thyroid disorders Any other acute infectious disease Females not willing for treatment

Design outcomes

Primary

MeasureTime frame
Effect of Ashwagandha Churna on Pre Menstrual SyndromeTimepoint: 1. After 1 month (At 28th day of 1st Menstrual cycle) 2. After 2 months (At 28th day of 2nd Menstrual cycle) 3. After 3 months (At 28th day of 3rd Menstrual cycle)

Secondary

MeasureTime frame
1. Conceptual understanding of PMS as per Ayurvedic principles. 2. Effect of other physiological factors in disease pathogenesis.Timepoint: During the study and also at the end of the intervention.

Countries

India

Contacts

Public ContactDr Deepika P Chaudhari

Shree Saptashrungi Ayurved Mahavidyalaya and Hospital

prakashachondikar@gmail.com9890096200

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026